Cargando…

Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis

AIM: This study aimed to predict the key targets and endocrine mechanisms of Guizhi Fuling Wan (GZFLW) in treating adenomyosis (AM) through network pharmacology, molecular docking, and animal experiment verification. METHODS: The related ingredients and targets of GZFLW in treating AM were screened...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Haoxian, Zhang, Jihong, Zhu, Qinqin, Fu, Xianyun, Li, Chenjie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563128/
https://www.ncbi.nlm.nih.gov/pubmed/34737779
http://dx.doi.org/10.1155/2021/6034147
_version_ 1784593369271369728
author Wang, Haoxian
Zhang, Jihong
Zhu, Qinqin
Fu, Xianyun
Li, Chenjie
author_facet Wang, Haoxian
Zhang, Jihong
Zhu, Qinqin
Fu, Xianyun
Li, Chenjie
author_sort Wang, Haoxian
collection PubMed
description AIM: This study aimed to predict the key targets and endocrine mechanisms of Guizhi Fuling Wan (GZFLW) in treating adenomyosis (AM) through network pharmacology, molecular docking, and animal experiment verification. METHODS: The related ingredients and targets of GZFLW in treating AM were screened out using TCMSP, BATMAN-TCM, SwissTargetPrediction, and PubChem Database. Then, the protein-protein interaction (PPI) analysis and the network of compound-hub targets were constructed. At the same time, the key targets were uploaded to the Metascape Database for KEGG pathway enrichment analysis. After that, the molecular docking technology of the main active components and hub targets was performed. Furthermore, animal experiments were used to verify the results of network pharmacology analysis. RESULTS: A total of 55 active ingredients of GZFLW and 44 overlapping targets of GZFLW in treating AM were obtained. After screening, 25 hub targets were collected, including ESR1, EGF, and EGFR. Then, the KEGG pathway enrichment analysis results indicated that the endocrine therapeutic mechanism of GZFLW against AM is mainly associated with the estrogen signaling pathway, endocrine resistance, and an EGFR tyrosine kinase signaling pathway. Then, molecular docking showed that the significant compounds of GZFLW had a strong binding ability with ERα and EGFR. More importantly, the animal experiments confirmed that the GZFLW could downregulate the abnormal infiltration of the endometrial epithelium into the myometrium and had no interference with the normal sexual cycle. This effect may be directly related to intervening the local estrogen signaling pathway of the endometrial myometrial interface (EMI). It may also be associated with the myometrium cells' estrogen resistance via GPER/EGFR signaling pathway. CONCLUSION: The endocrine mechanism of GZFLW in treating AM was explored based on network pharmacology, molecular docking, and animal experiments, which provided a theoretical basis for the clinical application of GZFLW.
format Online
Article
Text
id pubmed-8563128
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-85631282021-11-03 Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis Wang, Haoxian Zhang, Jihong Zhu, Qinqin Fu, Xianyun Li, Chenjie Evid Based Complement Alternat Med Research Article AIM: This study aimed to predict the key targets and endocrine mechanisms of Guizhi Fuling Wan (GZFLW) in treating adenomyosis (AM) through network pharmacology, molecular docking, and animal experiment verification. METHODS: The related ingredients and targets of GZFLW in treating AM were screened out using TCMSP, BATMAN-TCM, SwissTargetPrediction, and PubChem Database. Then, the protein-protein interaction (PPI) analysis and the network of compound-hub targets were constructed. At the same time, the key targets were uploaded to the Metascape Database for KEGG pathway enrichment analysis. After that, the molecular docking technology of the main active components and hub targets was performed. Furthermore, animal experiments were used to verify the results of network pharmacology analysis. RESULTS: A total of 55 active ingredients of GZFLW and 44 overlapping targets of GZFLW in treating AM were obtained. After screening, 25 hub targets were collected, including ESR1, EGF, and EGFR. Then, the KEGG pathway enrichment analysis results indicated that the endocrine therapeutic mechanism of GZFLW against AM is mainly associated with the estrogen signaling pathway, endocrine resistance, and an EGFR tyrosine kinase signaling pathway. Then, molecular docking showed that the significant compounds of GZFLW had a strong binding ability with ERα and EGFR. More importantly, the animal experiments confirmed that the GZFLW could downregulate the abnormal infiltration of the endometrial epithelium into the myometrium and had no interference with the normal sexual cycle. This effect may be directly related to intervening the local estrogen signaling pathway of the endometrial myometrial interface (EMI). It may also be associated with the myometrium cells' estrogen resistance via GPER/EGFR signaling pathway. CONCLUSION: The endocrine mechanism of GZFLW in treating AM was explored based on network pharmacology, molecular docking, and animal experiments, which provided a theoretical basis for the clinical application of GZFLW. Hindawi 2021-10-26 /pmc/articles/PMC8563128/ /pubmed/34737779 http://dx.doi.org/10.1155/2021/6034147 Text en Copyright © 2021 Haoxian Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Wang, Haoxian
Zhang, Jihong
Zhu, Qinqin
Fu, Xianyun
Li, Chenjie
Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
title Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
title_full Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
title_fullStr Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
title_full_unstemmed Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
title_short Integrating Network Pharmacology and Experimental Validation Deciphers the Mechanism of Guizhi Fuling Wan against Adenomyosis
title_sort integrating network pharmacology and experimental validation deciphers the mechanism of guizhi fuling wan against adenomyosis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8563128/
https://www.ncbi.nlm.nih.gov/pubmed/34737779
http://dx.doi.org/10.1155/2021/6034147
work_keys_str_mv AT wanghaoxian integratingnetworkpharmacologyandexperimentalvalidationdeciphersthemechanismofguizhifulingwanagainstadenomyosis
AT zhangjihong integratingnetworkpharmacologyandexperimentalvalidationdeciphersthemechanismofguizhifulingwanagainstadenomyosis
AT zhuqinqin integratingnetworkpharmacologyandexperimentalvalidationdeciphersthemechanismofguizhifulingwanagainstadenomyosis
AT fuxianyun integratingnetworkpharmacologyandexperimentalvalidationdeciphersthemechanismofguizhifulingwanagainstadenomyosis
AT lichenjie integratingnetworkpharmacologyandexperimentalvalidationdeciphersthemechanismofguizhifulingwanagainstadenomyosis